What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
Andrew Grigg mainly focuses on Internal medicine, Surgery, Leukemia, Immunology and Imatinib.
His Internal medicine research incorporates elements of Gastroenterology and Oncology.
The various areas that Andrew Grigg examines in his Surgery study include Clinical trial, Incidence and Hazard ratio.
The concepts of his Leukemia study are interwoven with issues in Autoimmune disease, Allogeneic transplantation and Intensive care medicine.
His Immunology study integrates concerns from other disciplines, such as Hematopoietic stem cell transplantation, Neutropenia and Fludarabine.
His work deals with themes such as Chronic myelogenous leukemia and Tyrosine-kinase inhibitor, which intersect with Imatinib.
His most cited work include:
- Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis (684 citations)
- Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia (656 citations)
- High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. (639 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Surgery, Transplantation, Oncology and Immunology.
Internal medicine and Gastroenterology are frequently intertwined in his study.
His Gastroenterology research is multidisciplinary, relying on both Granulocyte colony-stimulating factor and Fludarabine.
Andrew Grigg combines subjects such as Stem cell and Bone marrow with his study of Transplantation.
His Oncology study combines topics from a wide range of disciplines, such as Lymphoma and Rituximab.
His Imatinib research incorporates themes from Chronic myelogenous leukemia and Tyrosine-kinase inhibitor.
He most often published in these fields:
- Internal medicine (60.76%)
- Surgery (29.37%)
- Transplantation (22.87%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (60.76%)
- Oncology (21.08%)
- Transplantation (22.87%)
In recent papers he was focusing on the following fields of study:
Andrew Grigg focuses on Internal medicine, Oncology, Transplantation, Chemotherapy and Stem cell.
Internal medicine is a component of his Asymptomatic, Hematology, Lymphoma, Retrospective cohort study and Rituximab studies.
Andrew Grigg has researched Oncology in several fields, including Follicular lymphoma, Dexamethasone, Cohort and Clinical trial.
His work carried out in the field of Transplantation brings together such families of science as Congenital cytomegalovirus infection, Nivolumab and Leukemia, Immunology.
His research in Leukemia intersects with topics in Myeloid and Imatinib.
His research investigates the connection between Chemotherapy and topics such as Brentuximab vedotin that intersect with issues in Stage and Doxorubicin.
Between 2017 and 2021, his most popular works were:
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (182 citations)
- Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study (100 citations)
- Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial (51 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Oncology, Chemotherapy, Transplantation and Hematology.
Rituximab, Diffuse large B-cell lymphoma, Imatinib, Incidence and Adverse effect are the core of his Internal medicine study.
His biological study spans a wide range of topics, including Progression-free survival, Phases of clinical research, Chronic myelogenous leukemia, Follicular lymphoma and Nivolumab.
His Transplantation research is multidisciplinary, incorporating elements of Prednisolone, Humoral immunity, Antibody, Immunology and Stem cell.
His Hematology research includes elements of Cytarabine and Disease.
In his research on the topic of Myeloid leukemia, Imatinib mesylate is strongly related with Leukemia.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
